Avani to Represent Dermatology Products Featuring Invisicare(R)
LAS VEGAS, Dec. 6 /CNW/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI) /
(Website: http://www.skinvisible.com), is pleased to announce that it has
signed a marketing agreement with Avani International for India. This follows
Skinvisible's recent announcement that it was granted a comprehensive patent
in India for Skinvisible's proprietary polymer delivery system, Invisicare.
Invisicare enhances the delivery of topical dermatology products on the skin.
The agreement with Avani is part of Skinvisible's continued strategy to
quickly expand its reach around the globe. Avani will seek licenses in India
for topical products Skinvisible has developed for the treatment of acne,
fungal infections, atopic dermatitis and hand sanitizers. They will also
facilitate clinical studies and manufacturing in India.
"It is important for Skinvisible to develop partnerships with companies
such as Avani as they have established relationships with pharmaceutical and
consumer goods companies in India. This helps us fast track our marketing
efforts in the country and generate license fees and royalties quicker than
marketing in India ourselves," said Mr. Terry Howlett, President and CEO of
"India and its expanding population of over 1 billion people offers
tremendous market opportunities for Skinvisible and its Invisicare technology
and products," said Ash Chawla, Chairman & CEO of Avani. "This agreement
allows us to introduce Invisicare to Indian pharmaceutical manufacturers that
we know need this technology."
Skinvisible has patented its technology and trademarked its polymer
delivery system Invisicare(R). Invisicare is a combination of hydrophilic and
hydrophobic polymers that hold active ingredients on the skin for extended
periods of time. They are non-occlusive and allow normal skin respiration and
perspiration while moisturizing and protecting against exposure from a wide
variety of environmental irritants. See: http://www.Invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose
primary business objective is to license its proprietary formulations with
Invisicare(R) to pharmaceutical and cosmeceutical companies as well as
assisting companies in revitalizing or enhancing their existing skin care
products. Skinvisible receives a combination of research and development fees,
upfront license fees, and ongoing royalties for the life of the Invisicare
patent. See: http://www.skinvisible.com
About Avani International
Avani International is a leading business development firm, with services
ranging from product commercialization to launch, marketing, sales, and
distribution for pharmaceutical, biotechnology and medical device industries.
Avani enjoys strong relationships with manufacturers in India and has
pioneered relations and business growth between US and Indian companies for
the past five years. See: http://www.avaniinternational.com
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks and
uncertainties associated with an emerging company. Actual results could differ
materially from those projected in the forward looking statements as a result
of risk factors discussed in Skinvisible, Inc. reports on file with the U.S.
Securities and Exchange Commission (including, but not limited to, a report on
Form 10Q for the quarter ending September 30, 2007)
Terry Howlett, President/CEO
Skinvisible Pharmaceuticals, Inc
For further information:
For further information: Terry Howlett, President|CEO of Skinvisible
Pharmaceuticals, Inc., +1-702-433-7154, email@example.com Web Site: